Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United Airlines Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while United Airlines Holdings Inc trades at $124.66 (market cap $40.90B). The key difference: Alnylam Pharmaceuticals, Inc. and United Airlines Holdings Inc are close in size by market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | UAL | |
|---|---|---|
Market Cap | $39.89B | $40.90B |
Sector | Health | Industrials |
52-Week High | $491.22 | $136.11 |
52-Week Low | $278.09 | $84.57 |
Enterprise Value | $38.15B | $57.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
United Airlines (UAL) trades at $126.00, down 2.36% amid broader market volatility, with technical indicators showing a bullish trend near key support at $125. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.19 versus $1.08 expected, and robust profitability metrics like a 25.73% ROE. Recent news highlights Q2 2026 earnings anticipation on July 15, with analysts expecting $1.89 EPS, while expansion initiatives like new Cartagena routes signal growth momentum.
Outlook remains positive driven by earnings strength and analyst consensus, but risks include fuel cost spikes and legal challenges. The stock offers value with a low P/E of 11.27 and upside to the $160.88 price target, though investors should monitor oil price volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
